Teva Pharmaceutical Industries (TEVA) Long-Term Investments (2009 - 2012)

Teva Pharmaceutical Industries (TEVA) has reported Long-Term Investments for 4 consecutive years, with $1.2 billion the latest figure, recorded in Q3 2012.

• Quarterly Long-Term Investments rose 105.09% year-over-year to $1.2 billion in Q3 2012, while the trailing twelve-month figure through Sep 2012 was $1.2 billion (up 105.09% YoY) and the FY2011 annual result came in at $991.0 million, up 56.8% from the prior year.
• Long-Term Investments advanced to $1.2 billion in Q3 2012 per TEVA's latest filing, from $1.1 billion in the prior quarter.
• Over the last five years, Long-Term Investments for TEVA reached as high as $1.2 billion in Q3 2012 and fell as low as $406.0 million in Q1 2009.
• A 4-year average of $717.1 million and a median of $650.0 million in 2011 frame the typical range for Long-Term Investments.
• Annual changes were most pronounced in 2011 — Long-Term Investments decreased 13.38% — and 2012, when it surged 105.09%.
• Year by year, Long-Term Investments stood at $534.0 million in 2009, then advanced by 18.35% to $632.0 million in 2010, then soared by 56.8% to $991.0 million in 2011, then climbed by 21.9% to $1.2 billion in 2012.
• According to Business Quant data, Long-Term Investments over the past three periods registered $1.2 billion, $1.1 billion, and $1.0 billion for Q3 2012, Q2 2012, and Q1 2012 respectively.